Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 16, 2022

Long-Term Outcomes Following Pembrolizumab vs Chemotherapy as First-Line Therapy in Patients With NSCLC With PD-L1 Tumor Proportion Score ≥1%

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
J. Clin. Oncol 2022 Oct 28;[EPub Ahead of Print], G de Castro, I Kudaba, YL Wu, G Lopes, DM Kowalski, HZ Turna, C Caglevic, L Zhang, B Karaszewska, KK Laktionov, V Srimuninnimit, I Bondarenko, K Kubota, R Mukherjee, J Lin, F Souza, TSK Mok, BC Cho

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading